The Effects of Epoprostenol on Drug Disposition II: A Pilot Study of the Pharmacokinetics of Furosemide with and without Epoprostenol in Patients with Congestive Heart Failure

Carlton, Lisa D.; Patterson, J. Herbert; Mattson, Craig N.; Schmith, Virginia D.

doi:10.1002/j.1552-4604.1996.tb04196.x

Cited by 9 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sometimes, a large residual variability in the population pharmacokinetic model along with a relatively small number of pharmacokinetic samples precluded further analysis 71 …”

Section: Population‐based Methods Of Evaluating Drug‐drug Interactionsmentioning

confidence: 99%

“…70 Sometimes, a large residual variability in the population pharmacokinetic model along with a relatively small number of pharmacokinetic samples precluded further analysis. 71 Factors such as the number and timing of pharmacokinetic sampling points are thus essential to the successful completion of population-based assessments. Ideally, the number and timing of sampling points can be determined using optimal sampling theory.…”

Section: Potential Limitations and Important Points To Considermentioning

confidence: 99%

See 1 more Smart Citation

Population‐Based Assessments of Clinical Drug‐Drug Interactions: Qualitative Indices or Quantitative Measures?

Zhou¹

2006

The Journal of Clinical Pharma

View full text Add to dashboard Cite

Population-based assessments of drug-drug interactions have become more common since the introduction and acceptance of the population pharmacokinetic approach. Unlike traditional methods, population-based studies provide clinically relevant results that can be applied directly to a target patient population. Furthermore, population-based studies do not demand the traditional requirements of intensive pharmacokinetic sampling, rigorous inpatient stays, or stringent assessment schedules. As such, the population-based approach can effectively be used to confirm known drug-drug interactions and further characterize anticipated interactions. A prospectively designed analysis can also reveal drug-drug interactions that might otherwise have gone undetected with traditional methods. Ultimately, these results could help to alleviate clinicians' concerns about using widely marketed drugs in combination therapies and also reduce patients' risk of experiencing unacceptable side effects. This article intends to provide a balanced overview of the population-based approach and its merits, drawbacks, and potential utility in the assessment of drug-drug interactions during clinical drug development.

show abstract

“…Sometimes, a large residual variability in the population pharmacokinetic model along with a relatively small number of pharmacokinetic samples precluded further analysis 71 …”

Section: Population‐based Methods Of Evaluating Drug‐drug Interactionsmentioning

confidence: 99%

Section: Potential Limitations and Important Points To Considermentioning

confidence: 99%

Population‐Based Assessments of Clinical Drug‐Drug Interactions: Qualitative Indices or Quantitative Measures?

Zhou¹

2006

The Journal of Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…66 A similar study evaluating epoprostenol and furosemide showed that the clearance of furosemide was decreased by 13% when concomitantly administered with epoprostenol but this effect was neither statistically nor clinically significant. 67…”

Section: Epoprostenolmentioning

confidence: 99%

Drug Interactions Associated With Therapies for Pulmonary Arterial Hypertension

Narechania

Malesker

2022

Journal of Pharmacy Technology

View full text Add to dashboard Cite

Objective: To evaluate the potential for drug interactions with therapies for pulmonary arterial hypertension (PAH). Treatments include calcium channel blockers, phosphodiesterase type 5 inhibitors, endothelin receptor antagonists, guanylate cyclase stimulators, prostacyclin analogues, and prostacyclin receptor agonists. Data Sources: A systemic literature search (January 1980-December 2021) was performed using PubMed and EBSCO to locate relevant articles. The mesh terms used included each specific medication available as well as “drug interactions.” DAILYMED was used for product-specific drug interactions. Study Selection and Data Extraction: The search was conducted to identify drug interactions with PAH treatments. The search was limited to those articles studying human applications with PAH treatments and publications using the English language. Case reports, clinical trials, review articles, treatment guidelines, and package labeling were selected for inclusion. Data Synthesis: Primary literature and package labeling indicate that PAH treatments are subject to pharmacokinetic and pharmacodynamic interactions. The management of PAH is rapidly evolving. As more and more evidence becomes available for the use of combination therapy in PAH, the increasing use of combination therapy increases the risk of drug-drug interactions. Pulmonary arterial hypertension is also associated with other comorbidities that require concomitant pharmacotherapy. Conclusion: The available literature indicates that PAH therapies are associated with clinically significant drug interactions and the potential for subsequent adverse reactions. Clinicians in all practice settings should be mindful that increased awareness of drug interactions with PAH therapy will ensure optimal management and patient safety.

show abstract

The Effects of Epoprostenol on Drug Disposition II: A Pilot Study of the Pharmacokinetics of Furosemide with and without Epoprostenol in Patients with Congestive Heart Failure

Carlton

Patterson

Mattson

et al. 1996

The Journal of Clinical Pharma

View full text Add to dashboard Cite

The effect of epoprostenol on the pharmacokinetics of furosemide was investigated in 23 patients with end-stage congestive heart failure (CHF) receiving conventional therapy alone or conventional therapy plus epoprostenol. Estimates of the apparent oral clearance, volume of distribution, and absorption rate constant for furosemide were generated from 198 serum furosemide concentrations using nonlinear mixed effects modeling (NONMEM). Univariate analyses were performed to assess the effects of patient factors on the apparent oral clearance of furosemide. The final multivariate model determined by backwards elimination included concomitant digoxin therapy. When concomitant epoprostenol therapy was included in the final model, there was a 13% decrease in the apparent oral clearance of furosemide in response to short-term administration of epoprostenol. However, the effect of concomitant epoprostenol therapy was not statistically significant and was no longer apparent by the end of the 12-week study. These data suggest that epoprostenol may have a slight short-term effect on the pharmacokinetics of furosemide; the interaction between epoprostenol and furosemide is not clinically significant, however.

show abstract

The Effects of Epoprostenol on Drug Disposition II: A Pilot Study of the Pharmacokinetics of Furosemide with and without Epoprostenol in Patients with Congestive Heart Failure

Cited by 9 publications

References 18 publications

Population‐Based Assessments of Clinical Drug‐Drug Interactions: Qualitative Indices or Quantitative Measures?

Population‐Based Assessments of Clinical Drug‐Drug Interactions: Qualitative Indices or Quantitative Measures?

Drug Interactions Associated With Therapies for Pulmonary Arterial Hypertension

The Effects of Epoprostenol on Drug Disposition II: A Pilot Study of the Pharmacokinetics of Furosemide with and without Epoprostenol in Patients with Congestive Heart Failure

Contact Info

Product

Resources

About